Financial Performance - The company expects a net loss attributable to shareholders of between 70 million and 100 million yuan for the fiscal year 2024, compared to a profit of 45.604 million yuan in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 84 million and 114 million yuan, down from a profit of 24.529 million yuan in the previous year [3]. - The decline in performance is primarily due to a decrease in product prices, leading to reduced sales revenue and gross profit margin, with an estimated impact of approximately 40 million yuan on profits from high fixed costs [5]. - The company anticipates an impact of around 46 million yuan on profits due to inventory impairment as a result of declining intermediate product prices [5]. Cash Flow and Cost Management - The company aims to maintain a strong cash flow and has seen a significant increase in operating cash flow while slightly reducing period expenses compared to the previous year [6]. - In 2025, the company plans to enhance technology and optimize production processes to further reduce product costs and improve product quality and market competitiveness [6].
赛托生物(300583) - 2024 Q4 - 年度业绩预告